Pomalidomide price in 2025

Pomalidomide is regarded as one of the important breakthroughs in the treatment of multiple myeloma (MM). As a third-generation immunomodulator, it has anti-tumor, anti-angiogenic and immune-activating effects in terms of mechanism. It can effectively inhibit the growth of tumor cells and enhance the body's immune clearance ability against cancer cells. Compared with the early drugs thalidomide and lenalidomide, pomalidomide performs better in terms of persistence of efficacy and control of drug resistance, so it is often used to maintain or extend survival programs for patients after multiple lines of treatment.

The core advantage of this drug is that it has a high response rate for relapsed myeloma, delaying disease progression and improving quality of life. Its oral administration method is convenient and has good compliance, and it can be used in combination with dexamethasone and other drugs to form a multi-target combined inhibition program. Foreign studies have shown that pomalidomide can remain active under multiple resistance mechanisms, making it the "last line of defense" for many patients in treatment dilemmas.

In the domestic market, the original drug of pomalidomide has been introduced and launched by Boehringer Ingelheim, and has also been included in the national medical insurance directory. Although the price is higher, the financial burden on patients is significantly reduced after being reimbursed by medical insurance. The specific price varies depending on the region, hospital level and medical insurance policy. Patients can consult the local medical insurance designated hospital or pharmacy for actual reimbursement costs.

In addition to original drugs, there are currently generic versions from Laos, India and other places on the overseas market. Among them, Laotian generic drugs are the most affordable, usually about more than 300 yuan per box. The ingredients are the same as the original drugs, and the efficacy is comparable. However, when purchasing, you need to go through formal cross-border channels to ensure the quality and authenticity of the drugs.

Overall, the clinical benefits of pomalidomide include long-lasting efficacy, strong ability to control drug resistance, and flexible combination use. For patients already receiving treatments such as lenalidomide or bortezomib, it offers a viable option to continue treatment.

Reference materials:https://en.wikipedia.org/wiki/Pomalidomide